DrugPatentWatch Database Preview

Details for Patent: 7,078,412

« Back to Dashboard

Which drugs does patent 7,078,412 protect, and when does it expire?

Patent 7,078,412 protects TUDORZA PRESSAIR and is included in one NDA.

This patent has fifty-eight patent family members in thirty-four countries.

Summary for Patent: 7,078,412

Title:	Quinuclidine derivatives and medicinal compositions containing the same
Abstract:	The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.
Inventor(s):	Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee:	Almirall Prodesfarma AG (Baar, CH)
Application Number:	11/116,777
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,078,412
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,078,412

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Pharms	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y	Y		TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS

Foreign Priority and PCT Information for Patent: 7,078,412

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Spain	9901580	Jul 14, 1999

International Family Members for US Patent 7,078,412

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029760
Austria	235492
Australia	2005202144
Australia	6433000
Australia	779881
Bulgaria	106301